• Explore /
  • Poster
  • / Efficacy and safety of first-line (1L) nivolumab plus relatlimab (NIVO + RELA) versus NIVO plus ipilimumab (NIVO + IPI) in advanced melanoma: An indirect treatment comparison (ITC) using patient-level data (PLD).

Efficacy and safety of first-line (1L) nivolumab plus relatlimab (NIVO + RELA) versus NIVO plus ipilimumab (NIVO + IPI) in advanced melanoma: An indirect treatment comparison (ITC) using patient-level data (PLD).

Abstract Poster

Authors

null

Dirk Schadendorf

University Hospital Essen, University Duisburg-Essen, West German Cancer Centre (WTZ), and German Cancer Consortium, Partner Site Essen, Essen, Germany

Dirk Schadendorf , Hussein A. Tawbi , Evan J. Lipson , F. Stephen Hodi , Paolo Antonio Ascierto , James Larkin , Christopher D. Lao , Jean-Jacques Grob , Flavia Ejzykowicz , Andriy Moshyk , Viviana Garcia Horton , Jenny Zhou , Yiqiao Xin , Jennell Palaia , Laura McDonald , Sarah Keidel , Anthony Salvatore , Leon A. Sakkal , Georgina V. Long

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Melanoma/Skin Cancers

Track

Melanoma/Skin Cancers

Sub Track

Advanced/Metastatic Disease

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 9552)

DOI

10.1200/JCO.2023.41.16_suppl.9552

Abstract #

9552

Poster Bd #

315

Abstract Disclosures

Similar Posters

First Author: Ian Chau

First Author: F. Stephen Hodi

First Author: Celeste Lebbe

First Author: Hamid Emamekhoo